Cargando…

Intrinsic tumor resistance to CAR T cells is a dynamic transcriptional state that is exploitable with low-dose radiation

Chimeric antigen receptor (CAR) T-cell therapy represents a major advancement for hematologic malignancies, with some patients achieving long-term remission. However, the majority of treated patients still die of their disease. A consistent predictor of response is tumor quantity, wherein a higher d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Alexander B., Chou, Ssu-Yu, Kang, Solomon, Kwon, Eric, Inkman, Matthew, Szymanski, Jeff, Andruska, Neal, Colgan, Cian, Zhang, Jin, Yang, Joanna C., Singh, Nathan, DeSelm, Carl J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Immunobiology and Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509663/ https://www.ncbi.nlm.nih.gov/pubmed/37093643 http://dx.doi.org/10.1182/bloodadvances.2022009543

Ejemplares similares

Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma
por: Watanabe, Keisuke, et al.
Publicado: (2023)

A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy
por: Hirayama, Alexandre V., et al.
Publicado: (2022)

Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy
por: Holland, Elizabeth M., et al.
Publicado: (2022)

Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
por: Lamble, Adam J., et al.
Publicado: (2022)

Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc
por: O’Neal, Julie, et al.
Publicado: (2023)

Engineering amino acid uptake or catabolism promotes CAR T-cell adaption to the tumor environment
por: Panetti, Silvia, et al.
Publicado: (2022)

Host metabolome predicts the severity and onset of acute toxicities induced by CAR T-cell therapy
por: Jalota, Akansha, et al.
Publicado: (2022)

Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy
por: Kambhampati, Swetha, et al.
Publicado: (2022)

Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report
por: Fabrizio, Vanessa A., et al.
Publicado: (2022)

Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy
por: Juluri, Krishna R., et al.
Publicado: (2022)

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells
por: Michelozzi, Ilaria M., et al.
Publicado: (2022)

Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium
por: Stefanski, Heather E., et al.
Publicado: (2022)

Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden
por: Biondi, Marta, et al.
Publicado: (2023)

A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials
por: Silbert, Sara K., et al.
Publicado: (2023)

Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia
por: Dekker, Linde, et al.
Publicado: (2022)

HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma
por: Bourbon, Estelle, et al.
Publicado: (2022)

Off-the-shelf CAR–engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia
por: Mansour, Anthony G., et al.
Publicado: (2023)

Respiratory infections predominate after day 100 following B-cell maturation antigen–directed CAR T-cell therapy
por: Little, Jessica S., et al.
Publicado: (2023)

GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients
por: Gust, Juliane, et al.
Publicado: (2022)

Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma
por: Roddie, Claire, et al.
Publicado: (2023)

IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML
por: Perriello, Vincenzo Maria, et al.
Publicado: (2022)

SECTM1-based CAR T cells enriched with CD7-low/negative subsets exhibit efficacy in CD7-positive malignancies
por: Wei, Wenwen, et al.
Publicado: (2023)

CD38 as a pan-hematologic target for chimeric antigen receptor T cells
por: Glisovic-Aplenc, Tina, et al.
Publicado: (2023)

Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19
por: Osman, Mohammed, et al.
Publicado: (2020)

SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein
por: Keller, Michael D., et al.
Publicado: (2020)

Catch those antibodies before they fall
por: Shaz, Beth H., et al.
Publicado: (2020)

Expanding the toolbox to combat a pandemic
por: Prockop, Susan E.
Publicado: (2020)

Cytokine-induced natural killer cell training is dependent on cellular metabolism and is defective in obesity
por: Kedia-Mehta, Nidhi, et al.
Publicado: (2021)

Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production
por: Lee, Jong Bok, et al.
Publicado: (2021)

Defining the AHR-regulated transcriptome in NK cells reveals gene expression programs relevant to development and function
por: Trikha, Prashant, et al.
Publicado: (2021)

Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification
por: Martín Merinero, Hector, et al.
Publicado: (2021)

Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration
por: Nicolai, Leo, et al.
Publicado: (2022)

FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
por: Botta, Cirino, et al.
Publicado: (2022)

Sodium stibogluconate and CD47-SIRPα blockade overcome resistance of anti-CD20–opsonized B cells to neutrophil killing
por: van Rees, Dieke J., et al.
Publicado: (2022)

GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial
por: Ho, Vincent T., et al.
Publicado: (2022)

Antigen-specific immunotherapy with apitopes suppresses generation of FVIII inhibitor antibodies in HLA-transgenic mice
por: Pletinckx, Katrien, et al.
Publicado: (2022)

Neutrophil transit time and localization within the megakaryocyte define morphologically distinct forms of emperipolesis
por: Huang, Frank Y., et al.
Publicado: (2022)

Molecular bases for the association of FHR-1 with atypical hemolytic uremic syndrome and other diseases
por: Martin Merinero, Héctor, et al.
Publicado: (2021)

Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
por: Jiménez, Moraima, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n2ac736cgl4l3q59iin815lpfd